The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active substances / combinations of active substances within the framework of a so-called open house procedure. See the respective lot for details.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.

The subject of this publication is the conclusion of agreements in accordance with Section 130a (8) SGB V on various active ingredients / combinations of active ingredients within the framework of a so-called open house procedure. Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given under l.1). The email address named under Section I: Contracting Authority, Point 1.3.) Communication for the purpose of unrestricted and complete, free of charge access to the order documents does not exist. Information and the provision of the contract documents can be requested from the following email address: fp_open-house@nordost.aok.de. The prerequisite for the conclusion of a contract is that the interested pharmaceutical company submits the requested participation documents, completed in full and signed. Any pharmaceutical company that meets the prerequisites for participation and documents this by signing the declarations and the discount agreement can join the discount agreement. There is no exclusivity. The accession or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out. The start of the contract can only be the first of the month. The earliest contract start is May 1st, 2021. Based on this, the contract term is a maximum of 24 months. The contract ends on April 30th, 2023 at the latest, regardless of the date of the conclusion of the contract. At the start of the contract on May 1st, 2021, the offer must be available by March 24th, 2021, but AOK Nordost will not conclude any contracts before April 7th, 2021. For a later start of the contract, the submission deadline for the offers is the 5th of the respective previous month. (Example: contract start June 1st, 2021; deadline for submitting the offer: May 5th, 2021). If AOK Nordost grants an exclusive award for the active ingredient / active ingredient combination during the term of the contract as part of an open procedure, the contractual provisions concluded in this publication shall apply. This publication does not concern the award of a public contract within the meaning of the procurement coordination guideline 2014/24 / EU of the European Parliament and of the Council or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process designation open procedure, are solely due to the use of this announcement form and the publication platform. A further meaning, in particular submission to public procurement regulations, unless they are required for legal reasons, is not associated with this. An announcement of the awarded orders has been made exclusively on the website www.aok-gesundheitpartner.de since September 1st, 2016.